Latest Commercialization News

InVert Graphite has reported promising initial drilling results from its Kumba prospect in Tanzania, confirming consistent high-grade graphite mineralisation with grades reaching 13.4% Total Graphitic Carbon. The ongoing drilling program aims to further delineate this significant graphite resource ahead of the wet season.

Xamble Group reports a revenue rebound to A$1.7 million in Q3 2025 alongside narrowing EBITDA losses, reflecting early gains from its transformation strategy and technology investments.

Dotz Nano has extended the maturity dates of key convertible notes held by Mercer Street Capital Partners, signaling sustained investor confidence in its carbon capture technology and growth plans.

Tamboran Resources has sanctioned its Shenandoah South Pilot Project, completed a record drilling campaign, and is progressing infrastructure to deliver gas to the Northern Territory by mid-2026. The company also announced a planned acquisition of Falcon Oil & Gas and raised $56 million in a public offering.

DPM Metals delivered record third quarter financial results driven by strong free cash flow and adjusted net earnings, while its recent acquisition of Adriatic Metals' Vareš operation promises higher-than-expected production in 2026.

Biotron Limited’s lead HBV drug BIT-HBV001 demonstrates superior antiviral activity and synergy with the current standard treatment Tenofovir in preclinical models, advancing hopes for a more effective Hepatitis B therapy.

G50 Corp has initiated core drilling at its Golconda Project in Arizona, aiming to expand on a recent high-grade gold and silver discovery and explore new mineralisation zones. This move underscores the project's strategic importance amid growing demand for precious and strategic metals.

Bio-Gene Technology’s natural insecticide Qcide® has earned organic listing status from the US Organic Materials Review Institute, marking a pivotal step for its entry into the organic pest control market.

Island Pharmaceuticals will host a webinar to discuss the FDA's feedback on the clinical development and regulatory approval of its antiviral drug Galidesivir, including key considerations under the FDA's Animal Rule and Priority Review Voucher eligibility.

Besra Gold Inc reveals significant challenges at its Bau Gold Project, including mining lease renewal uncertainty and a reduction in measured gold resources, prompting a strategic pivot to government and community engagement before advancing development.

ReNerve Limited’s innovative NervAlign® Nerve Cuff has secured approval for use across the US Department of Defense and Veterans Affairs healthcare systems, marking a major milestone for the Australian medtech company.

Anteris Technologies has gained FDA approval to start patient recruitment in the US for its pivotal PARADIGM Trial, following initial European regulatory success. The company advances manufacturing and clinical readiness as it pushes toward key regulatory milestones.